The R&D point of view in the development of UNISTRAIN® PRRS.
Mar Fenech, a project manager at HIPRA’s R&D Department, highlights the most important factors: safety and efficacy are the key elements to developing a PRRS vaccine. UNISTRAIN® PRRS is a 21st-century vaccine that meets the extremely strict standards required by medicines agencies in different countries today.
Cross-protection in front of European field strains.
Nowadays, no one who knows about PRRS virus expects a universal protection from vaccines. However, HIPRA demonstrated the efficacy of UNISTRAIN® PRRS against several viruses ranging from 86 to 89 % of homology with the vaccine strain in ORF5.
From the laboratory to the multi-centric field trials.
During the development of the vaccine, numerous experiments and field tests were carried out in different sites and countries under VICH protocols. In all of them, safety and efficacy parameters were evaluated, which included local and general reactions, as well as the control of reproduction and production parameters in gilts, sows and piglets.
Interaction of UNISTRAIN® PRRS with the immune system.
Vaccination reduces the impact of the disease, although it does not necessarily provide full protection against the infection. Factors that may influence protection are the specific ability of the virus used in the immunisation to induce NAs or IFN-γ-SC and to modulate immune response.
The influence of HIPRA´s employees in UNISTRAIN® PRRS.
Jordi Ruano, Head of Biological Production at HIPRA, gives his point of view on the production of a PRRS vaccine: “In every production process our employees are a key element, and when it comes to the production of UNISTRAIN® PRRS, this is no different”.